Is CRISPR Therapeutics (CRSP) Pricing Look Attractive After Recent Share Price Weakness

Simply Wall St.03-29 19:08

If you are trying to figure out whether CRISPR Therapeutics is attractively priced or not, the recent share performance gives you a lot to think about. The stock last closed at US$45.75, with a 1.1% ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623356374?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-29 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623356374","market":"sg","top_or_hot":-1,"title":"Is CRISPR Therapeutics (CRSP) Pricing Look Attractive After Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>If you are trying to figure out whether CRISPR Therapeutics is attractively priced or not, the recent share performance gives you a lot to think about. The stock last closed at US$45.75, with a 1.1% ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-pricing-look-attractive-after-re\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is CRISPR Therapeutics (CRSP) Pricing Look Attractive After Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs CRISPR Therapeutics (CRSP) Pricing Look Attractive After Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-29 19:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-pricing-look-attractive-after-re><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are trying to figure out whether CRISPR Therapeutics is attractively priced or not, the recent share performance gives you a lot to think about. The stock last closed at US$45.75, with a 1.1% ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-pricing-look-attractive-after-re\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-pricing-look-attractive-after-re","article_id":"2623356374","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-pricing-look-attractive-after-re","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623356374","pubTimestamp":1774782500,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are trying to figure out whether CRISPR Therapeutics is attractively priced or not, the recent share performance gives you a lot to think about.\nThe stock last closed at US$45.75, with a 1.1% decline over 7 days, a 23.9% decline over 30 days, a 14.9% decline year to date, but a 23.7% gain over 1 year and a 1.1% gain over 3 years compared to a 61.7% decline over 5 years.\nThese shifts in returns have kept CRISPR Therapeutics on many watchlists, as investors weigh shorter term weakness...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4556":"基因编辑","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4139":"生物科技","LU1861558580.USD":"日兴方舟颠覆性创新基金B","CRSP":"CRISPR Therapeutics AG","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4611":"AI医疗","BK4588":"碎股"},"translate_title":"近期股价疲软后，CRISPR Therapeutics(CRSP)的定价看起来有吸引力吗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":1.5,"DCF":1},"content_text":"If you are trying to figure out whether CRISPR Therapeutics is attractively priced or not, the recent share performance gives you a lot to think about. The stock last closed at US$45.75, with a 1.1% decline over 7 days, a 23.9% decline over 30 days, a 14.9% decline year to date, but a 23.7% gain over 1 year and a 1.1% gain over 3 years compared to a 61.7% decline over 5 years. These shifts in returns have kept CRISPR Therapeutics on many watchlists, as investors weigh shorter term weakness against longer term moves. Recent coverage has focused on how sentiment toward gene editing and related therapies can influence interest in the stock, which helps explain why price swings can be sharp even without company specific headlines. On Simply Wall St's valuation checks, CRISPR Therapeutics currently scores 3 out of 6, as shown in the valuation score. Next you will see how different valuation approaches line up on this stock, along with one more way to think about value that can be even more helpful by the end of the article.  CRISPR Therapeutics delivered 23.7% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementApproach 1: CRISPR Therapeutics Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes estimates of future cash flows and discounts them back to today using a required rate of return, giving an estimate of what the entire stream of cash is worth in today’s dollars. For CRISPR Therapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach, based on projected free cash flows in $. The latest twelve month free cash flow is a loss of $345.4 million, and analyst and extrapolated forecasts range from a loss of $402.2 million in 2026 to positive free cash flow of $1,115.3 million in 2035. The 2030 projection alone is $204.5 million. Earlier years are based on analyst estimates, while later years are extrapolated by Simply Wall St from those inputs. When these projected cash flows are discounted back, the model arrives at an estimated intrinsic value of US$191.29 per share. Compared with the recent share price of US$45.75, the DCF output implies the stock is 76.1% undervalued. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests CRISPR Therapeutics is undervalued by 76.1%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks. CRSP Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for CRISPR Therapeutics. Approach 2: CRISPR Therapeutics Price vs Book For companies where earnings are not yet a steady guide, price based on book value can be a useful cross check, as it anchors the valuation to the net assets on the balance sheet rather than short term profits. In general, investors tend to accept a higher P/B ratio when they expect stronger growth or see lower risk, and a lower P/B when growth is uncertain or risks are higher. So what counts as a “normal” or “fair” P/B really depends on those growth and risk expectations. CRISPR Therapeutics currently trades on a P/B of 2.28x. That is very close to the Biotechs industry average of 2.22x and below the peer group average of 8.25x. This suggests the stock is being valued more in line with its sector than with higher rated peers. Simply Wall St also calculates a proprietary “Fair Ratio”, which is the P/B multiple it would expect for CRISPR Therapeutics after factoring in its earnings profile, growth outlook, profit margins, industry, market cap and specific risks. Because this pulls together those company specific drivers, it can be a more tailored benchmark than simple peer or industry comparisons. In this case, there is no Fair Ratio figure available, so it is not possible to reach a conclusion on whether the current P/B is overvalued, undervalued, or about right using this method alone. Result: ABOUT RIGHT NasdaqGM:CRSP P/B Ratio as at Mar 2026 P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies. Upgrade Your Decision Making: Choose your CRISPR Therapeutics Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives are a way for you to attach a clear story to your numbers by linking your assumptions about CRISPR Therapeutics future revenue, earnings and margins to a forecast, and then to your own view of fair value. On Simply Wall St, Narratives are available on the Community page and are designed so any investor can quickly set a fair value, compare it to the current price, and use that gap to help decide whether the stock belongs on a watchlist, is closer to a buy zone, or looks stretched. Each Narrative updates as fresh information arrives, such as new earnings or company news. This means your story and the implied fair value move with the facts rather than sitting static. For CRISPR Therapeutics, some Narratives on Simply Wall St set a very optimistic fair value while others use far more conservative assumptions. This shows how different investors can look at the same company, the same cash flow forecasts and the same P/B of 2.28x, yet reach very different conclusions. Do you think there's more to the story for CRISPR Therapeutics? Head over to our Community to see what others are saying! NasdaqGM:CRSP 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623356374","isCrawlerRequest":true}